Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia

2010 ◽  
Vol 10 (5) ◽  
pp. 361-368 ◽  
Author(s):  
Susan O'Brien ◽  
Anders Österborg
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Antibody Therapy ◽  
Lymphocytic Leukemia ◽  
Monoclonal Antibody Therapy ◽  
Cell Chronic Lymphocytic Leukemia

A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells

1994 ◽  
Vol 39 (2) ◽  
pp. 137-146 ◽  
Author(s):  
P. Tassone ◽  
P. Bonelli ◽  
F. Tuccillo ◽  
H.M. Bond ◽  
M.C. Turco ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Lymphocytic Leukemia ◽  
Leukemia Cells ◽  
Cell Chronic Lymphocytic Leukemia

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Blood ◽  
2002 ◽  
Vol 100 (3) ◽  
pp. 768-773 ◽  
Author(s):  
Jeanette Lundin ◽  
Eva Kimby ◽  
Magnus Björkholm ◽  
Per-Anders Broliden ◽  
Fredrik Celsing ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Bone Marrow ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Lymphocytic Leukemia ◽  
Prolonged Treatment ◽  
Line Treatment ◽  
First Line ◽  
Cell Chronic Lymphocytic Leukemia ◽  
First Line Treatment

Abstract This phase II study determined the efficacy and safety of alemtuzumab, a humanized anti-CD52 monoclonal antibody, delivered subcutaneously as first-line therapy, over a prolonged treatment period of 18 weeks in 41 patients with symptomatic B-cell chronic lymphocytic leukemia (B-CLL). Injections were administered subcutaneously 3 times per week, from week 2 to 3 onward. An overall response rate (OR) of 87% (95% CI, 76%-98%; complete remission [CR], 19%; partial remission [PR], 68%) was achieved in 38 evaluable patients (81% of intent-to-treat population). CLL cells were cleared from blood in 95% patients in a median time of 21 days. CR or nodular PR in the bone marrow was achieved in 66% of the patients and most patients achieved this after 18 weeks of treatment. An 87% OR (29% CR) was achieved in the lymph nodes. The median time to treatment failure has not yet been reached (18+ months; range, 8-44+ months). Transient injection site skin reactions were seen in 90% of patients. Rigor, rash, nausea, dyspnea, and hypotension were rare or absent. Transient grade IV neutropenia developed in 21% of the patients. Infections were rare, but 10% patients developed cytomegalovirus (CMV) reactivation. These patients rapidly responded to intravenous ganciclovir. One patient, allergic to cotrimoxazole prophylaxis, developedPneumocystis carinii pneumonia. Alemtuzumab is highly effective as first-line treatment in patients with B-CLL. Prolonged treatment is important for maximal bone marrow response. Subcutaneous administration induced very few “first-dose” flulike symptoms and may reduce health care costs in comparison with the intravenous infusions.

scholarly journals Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2303
Author(s):  
Verena Barbarino ◽  
Sinika Henschke ◽  
Stuart Blakemore ◽  
Elena Izquierdo ◽  
Michael Michalik ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Cell Lymphoma ◽  
Antibody Therapy ◽  
B Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
Janus Kinase ◽  
Monoclonal Antibody Therapy ◽  
Antibody Treatment ◽  
Btk Inhibitors

Targeted inhibition of Bruton’s Tyrosine Kinase (BTK) with ibrutinib and other agents has become important treatment options in chronic lymphocytic leukemia, Waldenström’s Macroglobulinemia, Mantle cell lymphoma, and non-GCB DLBCL. Clinical trials combining small molecule inhibitors with monoclonal antibodies have been initiated at rapid pace, with the biological understanding between their synergistic interactions lagging behind. Here, we have evaluated the synergy between BTK inhibitors and monoclonal antibody therapy via macrophage mediated antibody dependent cellular phagocytosis (ADCP). Initially, we observed increased ADCP with ibrutinib, whilst second generation BTK inhibitors failed to synergistically interact with monoclonal antibody treatment. Kinase activity profiling under BTK inhibition identified significant loss of Janus Kinase 2 (JAK2) only under ibrutinib treatment. We validated this potential off-target effect via JAK inhibition in vitro as well as with CRISPR/Cas9 JAK2−/− experiments in vivo, showing increased ADCP and prolonged survival, respectively. This data supports inhibition of the JAK-STAT (Signal Transducers and Activators of Transcription) signaling pathway in B-cell malignancies in combination with monoclonal antibody therapy to increase macrophage-mediated immune responses.

Inhibition of human B-cell chronic lymphocytic leukemia by a monoclonal antibody in xenograft models

1994 ◽  
Vol 56 (3) ◽  
pp. 439-445 ◽  
Author(s):  
Zhenping Zhu ◽  
Tarunendu Ghose ◽  
David Hoskin ◽  
Christine L. Y. Lee ◽  
Louis A. Fernandez ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Lymphocytic Leukemia ◽  
Xenograft Models ◽  
Cell Chronic Lymphocytic Leukemia ◽  
Human B Cell

A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells

1994 ◽  
Vol 40 (1) ◽  
pp. 81
Author(s):  
P. Tassone ◽  
P. Bonelli ◽  
F. Tuccillo ◽  
H.M. Bond ◽  
M.C. Turco ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Lymphocytic Leukemia ◽  
Leukemia Cells ◽  
Cell Chronic Lymphocytic Leukemia

Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia

2004 ◽  
Vol 5 (6) ◽  
pp. 546-547 ◽  
Author(s):  
Despina Pantelidou ◽  
Costas Tsatalas ◽  
Dimitris Margaritis ◽  
Vasiliki Kaloutsi ◽  
Emmanuel Spanoudakis ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Pure Red Cell Aplasia ◽  
Lymphocytic Leukemia ◽  
Red Cell ◽  
Red Cell Aplasia ◽  
Anti Cd20 ◽  
Cell Chronic Lymphocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document